RESEARCH DOSSIER
Risk Governance of New Insurance Products and Innovations
Abstract. The development of new insurance products changes the composition of an insurer's liabilities, the information on which underwriting decisions rest, the behavior of intermediaries and policyholders, and the operational dependencies required to perform contractual promises. Product innovation therefore presents a governance question extending from initial concept approval to claims performance, solvency, and corrective action. This research investigates the organization and evidential quality of that governance through comparative analysis of international supervisory principles, European product oversight and prudential legislation, British product-value rules and supervisory evidence, United States state-based supervisory instruments, and peer-reviewed empirical research. The central finding is that product approval becomes substantively effective when the decision record links the promised coverage, identifiable customer population, available loss evidence, plausible tail scenarios, distribution behavior, operational deliverability, and enterprise capital capacity to a decision-maker empowered to impose constraints. These links remain necessary after launch because innovation changes both exposure and knowledge. The European product-oversight regime expressly integrates premarket approval and continuing review; United States requirements depend on enacted state law, while model guidance supplies a distinct reference point. British evidence shows that implementation quality and demonstrable customer value remain material challenges even where formal processes exist. Actuarial illustrations establish the consequences of parameter uncertainty and the difference between expected loss and predictive variability; they are transparently hypothetical and do not estimate any insurer's realized results. The study develops original comparative judgments concerning the evidential burden at launch, proportional decision rights, cross-functional dependencies, and the meaning of postlaunch product surveillance. It establishes no new named theory, regulatory requirement, causal estimate, or universal numerical launch threshold. The resulting synthesis places policyholder performance, balance-sheet resilience, and the capacity to reverse an unsafe innovation within one continuous enterprise decision process.
Keywords: Insurance product innovation; product oversight and governance; enterprise risk management; new product approval; underwriting uncertainty; actuarial credibility; risk appetite; scenario analysis; target market; consumer value; model risk; cyber insurance; parametric insurance; operational resilience; postlaunch monitoring; corrective action.
Introduction
An insurance product is an intertemporal contractual arrangement. Premiums may be collected before the frequency, severity, adjudication, and cost of covered events become known. For an established portfolio, experience can partly discipline these uncertainties; for a genuinely new coverage, distribution design, trigger, or exposure class, history is often weakly transferable. The insurer is simultaneously deciding which promises it can perform, which customers can reasonably use those promises, how a contract will be sold, and how much contingent liability the enterprise can absorb. The governance object is the complete prospective relationship among those decisions.
The Insurance Distribution Directive's product-governance rule makes the connection unusually clear: manufacturers must approve products or significant adaptations before distribution, identify target markets, assess associated risks, align distribution, and revisit products when circumstances change. The Solvency II risk-management provisions address another necessary dimension: underwriting, reserving, reinsurance, operational and other risks must enter an integrated risk-management system. They are related obligations with different legal objects. A profitable product can fail its customer purpose; a product with plausible customer benefit can threaten the firm's capacity to pay; a technically solvent design can fail through a third-party data or claims service.
This monograph asks three questions. First, what qualifies as a new-product risk-governance decision and how do insurer-level risk controls differ from product oversight? Second, how should governance address sparse losses, unstable perils, distribution incentives, technology dependencies, and conflicting signals of value? Third, which conclusions are actually supported by law, supervisory observation, and insurer research, and which can only be explored through hypothetical calculations?
The research method is a critical, source-traceable comparison of primary supervisory texts and public research records. The analysis distinguishes binding EU legislation, UK regulatory rules, international standard-setting principles, voluntary standards, US model instruments, and academic results. It compares the original institutional objects and the operative versions identifiable at the November 15, 2026 cutoff. It does not represent a systematic review or a census of national state implementations. Publisher abstracts and institutional repositories are used where full scholarly articles were not openly accessible, and the resulting limits are stated. No proprietary insurer product-committee minutes, pricing files, or policyholder-level claims data were obtained. All mathematical examples are derived in this text from explicitly assumed numbers. The relevant source URLs and their claim-specific verification scopes are preserved in EVIDENCE.json.
The scope is anchored in Enterprise Risk Management in Insurance, the established principal Science area. Companion subjects—risk appetite, model validation, underwriting, reinsurance, compliance, and conduct—remain independent fields. The object here is the point at which their evidence and decision rights must converge around a specific innovation, followed by a test of whether that innovation performs as assumed.
Definitions, History, and Documentary Foundation
Product innovation as a change in the liability promise
A new insurance product may involve new insured events, newly defined populations, novel trigger or payout mechanisms, differentiated deductibles, services bundled with insurance, automated underwriting, a changed channel, or a transformation of existing coverage large enough to affect its original risk allocation. These changes are analytically distinct. An unfamiliar claim peril primarily challenges loss modeling; an embedded distribution model also changes consent, incentives, and the information available to buyers; parametric payout rules introduce basis risk; digital claims adjudication raises continuity and decision-quality questions.
For governance purposes, novelty is assessed relative to the insurer's evidence, capabilities, contracts, and existing portfolio, not merely the marketing label. A product already common in another market can be new to a particular balance sheet, jurisdiction, or distribution system. Conversely, an apparently modest endorsement can materially widen an exclusion, change a correlated exposure, or create a previously absent legal obligation. This relative definition is an analytical judgment: novelty grows with the mismatch between the enterprise's inherited controls and the proposed liability, rather than with promotional language.
The OECD insurer-governance guidelines describe insurance organizations as risk-accepting institutions whose governance must protect contractual beneficiaries and maintain sound management. The ISO 31000:2018 risk-management guidance provides a broader vocabulary of risk identification, assessment, treatment, monitoring, and communication; it is voluntary guidance, not an insurance license or a legal product-approval regime. The IAIS supervisory principles supply an internationally recognized reference for supervisory risk management and conduct, whose application depends on jurisdictional implementation. Together they illuminate functions of governance while retaining their different normative status.
Documentary evolution of oversight obligations
The development of formal new-product governance reflects the convergence of prudential management, conduct supervision, and technological control. Prudential supervision asks whether insurers can meet obligations in adverse conditions. Conduct supervision asks whether the promised protection fits the needs of customers and is distributed appropriately. Innovation introduces dependencies—data, platforms, partners and algorithms—that can impair both outcomes at once. Each concern has its own lineage and regulatory instrument; an insurer must resolve their intersections in the proposed product.
Article 25 of the 2016 Insurance Distribution Directive creates requirements for manufacturers' approval and review arrangements. The 2017 product-governance delegated regulation further addresses written approval policies, target-market identification, appropriate product testing, scenarios, distribution arrangements, monitoring, and remedial action. Its notion of a manufacturer extends to intermediaries that exercise genuine decision-making power over essential product features; contractual labels alone therefore cannot settle allocation of regulatory responsibility. A customized contract requested by one customer is treated differently from manufacturing a product for the market under that instrument.
Solvency II, particularly the integrated-risk provisions of Articles 44–45, requires the undertaking to view risks individually and in aggregate, including their interdependencies, and to conduct its own risk and solvency assessment. The requirement to consider risks outside or incompletely captured by the standard capital calculation matters for innovation: a product's historical loss volatility may be estimable while contractual uncertainty, mass-market distribution, or technology aggregation remains less tractable. Its formal ORSA requirements apply according to EU law and the relevant implementing framework; this text does not make a one-for-one equation between product committee approval and the statutory ORSA.
Across the Atlantic, the NAIC ORSA description explains the US state-based framework associated with Model Act #505 and the need to evaluate current and prospective risks. A model act is a template for state enactment, and applicable law must be determined by the state of domicile and business activity. The SERFF filing infrastructure facilitates rates and forms submissions across jurisdictions; the existence of electronic filing infrastructure does not create universal substantive product-approval rules. The distinction is fundamental to international comparison: internal product authorization, a filed rate or form, and formal regulatory permission may be three different events.
Risk governance, product governance, and model governance
Insurer risk governance concerns the allocation of decision authority over the enterprise's risk profile and survival capacity. Product oversight concerns the design, target market, distribution, value, and correction of a particular offering. Model governance addresses the quality, limitations, documentation, validation, and change control of the quantitative or algorithmic instruments used within those decisions. These domains intersect when a model produces a proposed premium and the product owner seeks approval, but they test different propositions.
A valid frequency model is evidence about selected stochastic properties under specified conditions. It is not proof that policy wording resolves a coverage dispute, that customer information is intelligible, or that a reinsurance contract responds when the original policy pays. Similarly, a comprehensive product review may fail to assess the accumulation of related exposures across divisions. A credible launch decision therefore requires a coordinated evaluation with recorded disagreements and identifiable authority. This conclusion follows from the separation of legal and analytical functions, rather than from a claim that every insurer must use the same committee structure.
The IAIS ICP framework assigns distinct but coordinated roles to governance and control functions; risk, compliance, actuarial, and internal-audit activities contribute different information. The OECD governance reference likewise locates accountability in organizational structures rather than merely in paperwork. The scientific implication is that the existence of a signed approval form is a weak proxy for the quality of the underlying decision.
Research design, evidence hierarchy, and limits
Primary legislation and official consolidated rules are used to identify legal obligations as described at the cutoff; they are separated from supervisory opinions, technical standards, and public commentaries. Supervisory thematic reviews are direct evidence of what an authority examined and reported in its sampled firms, not of a universal market prevalence. Peer-reviewed observational studies may identify associations conditional on their empirical design; they do not establish causal effects of a specific launch gate.
This hierarchy is critical when comparing the widely cited Hoyt and Liebenberg (2011) ERM study with McShane, Nair, and Rustambekov (2011). The former reports a positive relationship between ERM adoption and Tobin's Q in a US insurer sample, with a roughly 20% valuation premium in its modeled results. The latter finds a positive association with increasing traditional risk-management capability but no further incremental firm-value increase at higher ERM ratings. Their measures, designs, and exposures differ. Neither identifies the causal effect of a particular new-product committee, nor supports an unqualified prediction that additional control stages increase shareholder value.
Scientific interpretation therefore rests on mechanism and documented constraints: a gate is valuable if it changes the information and decision under uncertainty in a direction consistent with the insurer's contractual and risk objectives. Direct empirical validation of that mechanism would require longitudinal decision records and policy-level outcomes, which this dossier does not possess.
New Product Risk Gates
Establishing a decision object and an accountable authority
A launch request should identify the legally responsible risk carrier, proposed policy forms, insured population, geographic scope, premium and commission structure, event triggers, waiting periods, exclusions, limits, claims operations, data sources, technology and outsourcing dependencies, expected growth, and plausible adverse outcomes. The governing body then decides what evidence is sufficient and which residual risks it authorizes. This minimum analytical record follows from the specific ways that an incomplete product description makes apparently precise risk estimates meaningless.
The EU delegated product-governance rules explicitly require a written approval process for new or significantly adapted products. For each launch, the insurer should document whether an intermediary independently determined essential product characteristics and thus qualifies as a manufacturer under the applicable regime. Third-party design or distribution does not automatically extinguish the manufacturer's obligations. Product design and distribution therefore share a governance record even if separate entities perform the functions.
A coherent committee process requires the product sponsor to present an executable contract, the actuarial function to challenge expected losses and uncertainty, risk management to consider aggregate profile and limits, legal and compliance functions to examine obligations and sales, operations to demonstrate claims deliverability, and independent challenge to identify material missing evidence. The authority to refuse, delay, limit, or amend launch must be identifiable. Delegation can be proportional to risk materiality, but an enterprise-wide exposure must remain visible to those responsible for total capacity.
Testing the contract against the customer and the risk carrier
Customer suitability and insurer risk appetite are separate test domains. For customers, the question is whether the insured population faces the defined peril, understands the coverage and restrictions, and receives a credible route to an actual payment when the covered loss occurs. For the risk carrier, the question is whether the price, risk assumptions, portfolio mix, reinsurance, operational resources, and capital remain acceptable when stressed.
The target-market requirements in Article 25 are operationally relevant at the decision point: distribution cannot be assumed to be appropriate solely because the actuarial tariff is sound. In the UK, FCA PROD 4 product rules address product manufacturing, value and distribution for the covered product classes. The UK rules include an assessment of whether the price-quality relationship offers fair value, and the current text requires changes or withholding from marketing where demonstrable fair value is absent. Precise obligations depend on classification and applicable handbook provisions; the EU and UK texts should not be conflated.
A useful internal challenge asks how a claim can be declined despite the customer's reasonable reading of the marketing statement. Consider a rainfall policy that promises rapid recovery after severe precipitation but pays only when a remote gauge records a specified threshold. Even perfectly administered automatic payments may leave damaged customers without indemnity. The target-market test must identify such basis risk as a property of contract design; the balance-sheet test must quantify the behavior of the chosen trigger. A single product may pass the technical payout-system test and still fail the purpose articulated to its customers.
Pricing, risk appetite, and portfolio interaction
Let denote the random total incremental claims of a new product over one year, the premium income, expected acquisition and servicing expenditure, and a risk-capital allocation or support requirement. A simplified prospective underwriting contribution is ; it is an accounting-free illustration, not an IFRS 17 profit formula or regulatory solvency calculation. This quantity must be considered along with uncertainty in , timing and liquidity, claims tail risk, and dependence with existing portfolio losses .
Under a finite-variance approximation, aggregate variability is
The covariance term is precisely why apparently attractive innovation may alter enterprise resilience. A cyber product written for thousands of policyholders using the same cloud provider can create a common-shock dependence whose scale is absent from the price model based on independent claims. A climate product that duplicates existing catastrophe-zone exposure can increase tail concentration despite a favorable stand-alone mean. The Solvency II risk-management text and IAIS principles on enterprise risk support the requirement to evaluate interdependencies, though they do not prescribe this elementary variance identity as a legal capital formula.
An approval that only states expected margin omits the range of states in which the product threatens policyholder security. Pricing approval, claims capability, reinsurance response, and portfolio capacity must therefore be reviewed together. A reinsurance letter of intent cannot be counted as an executed transfer; a modelled risk reduction cannot be assumed if attachment, exclusions, currency, event definitions, or recoverability differ from the underlying liability.
Transparent hypothetical launch arithmetic
Consider an entirely hypothetical one-year product with 10,000 policies, an assumed annual claim probability of 1.2%, a conditional mean claim of $4,000, gross premium of $75 per policy, and acquisition and administrative costs of $15 per policy. Assume one claim at most per policy and disregard investment income, tax, reserve development, discounting, correlation, and capital costs. Expected claims are . Premium income is $750,000; modeled operating expenses are $150,000; expected contribution on the stated assumptions is $120,000.
Now hold severity and expenses fixed and vary claim probability between 0.8% and 2.0%. Expected claims move from $320,000 to $800,000. Prospective contribution ranges from $280,000 to negative $200,000 before any capital charge. These are conditional scenario outcomes, not confidence intervals and not predictions of an actual insurer. They illustrate a decision criterion: authorization based solely on the point estimate 1.2% is materially more permissive than authorization that recognizes plausible alternative frequencies.
The appropriate governance response need not be automatic rejection. The board or delegated committee may limit initial volume, adjust coverage, secure reinsurance, add monitoring, obtain new evidence, or retain a documented contingency. Each alternative changes a different part of the risk. A cap on sold policies reduces maximum liability but does not correct misleading policy wording; a higher premium may improve modeled financial margin but worsen the product's assessed value for the target market. The decision record must say which problem each condition addresses.
Conditional approval and organizational learning
A product can be launched with an explicit, measurable, time-limited scope where evidence is sufficient for a constrained exposure and there is a practicable correction mechanism. Conditional approval should specify what is authorized, which model uncertainty is accepted, what claim and complaints signals will be monitored, who may expand volume, and what event automatically returns the product to review. This is a general governance inference rather than a new regulatory doctrine.
The relevance of a conditional launch is especially clear for untested partnerships. Distribution may be rolled out faster than insurer experience can emerge. If approval is written without a volume cap, a denominator for monitoring, and a deadline for review, the absence of observed claims may be mistaken for proof of safety. A low observed loss count can be equally compatible with a safe design, a delayed claim reporting process, or extremely low exposure. Underwriting and sales data must share consistent exposure units before performance can be interpreted.
In the 2024 FCA product-governance thematic review, the regulator reviewed information from 28 manufacturers and 39 distributors across 10 products and found weaknesses in demonstrating fair value and effective action. These figures describe the review's sampled coverage, not the proportion of all British insurers that fail their obligations. The evidence supports a practical conclusion: the existence of a formal product cycle is insufficient if evidence of decisions and customer outcomes is missing.
Sparse Data and Peril Uncertainty
Distinguishing the absence of evidence from low expected loss
Novel insurance risk often suffers from small samples, claims development delay, selection bias, reporting changes, product redesign, uncertain legal interpretation, or structural change in the hazard itself. Observed frequency is an estimator conditioned on exposure and reporting; it is not a timeless physical property. A risk can appear rare because the insurer has insured few units, because the loss period is short, because incident reporting is inconsistent, or because the triggering event has not yet occurred.
Cyber insurance provides a clear empirical example. Biener, Eling, and Wirfs (2015) analyzed 994 cyber loss cases drawn from an operational risk database and identified data limitations, interrelated losses, and information asymmetries as obstacles to insurance. Their database is not a representative random sample of every insured cyber exposure. The later Eling and Schnell (2016) review surveyed 209 papers and emphasized the difficulty of changing risks, limited data, and accumulation. These studies justify heightened model and scenario scrutiny, not an assertion that cyber risks are universally uninsurable.
The same epistemic distinction applies to emerging climate coverages, autonomous operations, new health risks, and parametric schemes. Historical data can be valuable when its generating conditions remain relevant. When technology, reporting, exposure composition, or legal obligations change, the need to justify transferability increases. A governance gate should record the source population, the product's proposed population, the differences, and the scenarios under which those differences become material.
Compound loss models and the problem of transferability
A conventional aggregate claims representation writes
where is claim count and denotes severity. Under independent, identically distributed severities independent of , the familiar moment identities are and . These identities depend on explicit assumptions. They can be inappropriate for event-driven, contagion, common-vendor, or inflation-sensitive portfolios where count and severity move together.
A pricing file may give a numerically stable best estimate while its sample excludes extreme events and its assumed dependence structure is implausible. The actuarial question is not only whether a parameter can be estimated, but whether the model's representation of an insured event corresponds to the actual contract under emerging conditions. Narrative stress descriptions are insufficient when their effect on aggregate loss, liquidity, reinsurance, and available capital remains unevaluated.
The 2025-consolidated Solvency II directive requires integrated management of risks, including those not fully captured in a capital metric. This prudential obligation supports a disciplined use of alternative scenarios even when a precise probability for an innovation shock is unavailable. Scenario analysis is particularly suitable for examining discontinuous legal reinterpretations and shared-platform failures whose statistical history is too short for reliable extrapolation.
Bayesian illustration of parameter risk
Consider an illustrative homogeneous Poisson claim-count process with constant annual intensity per policy-year. Assume a Gamma prior with shape and rate , so prior mean intensity is . If an independently observed sample contains claims over exposure-years, the conjugate posterior is . The posterior mean is claims per policy-year, distinct from the crude sample rate .
Under this stated model, for a future block with exposure-years, the posterior predictive expected claim count is . Its variance is
The plug-in Poisson predictive variance would be only approximately 14.286, because it treats the posterior mean intensity as known. The larger predictive variance reflects parameter uncertainty, not direct evidence of a specific real insurer's claim behavior. The numerical prior is illustrative; different defensible priors and heterogeneous exposure structures can produce different answers. This is a familiar Bayesian calculation applied here for explanation, not a new actuarial model or a newly estimated claim distribution.
A launch gate should consequently require the modeler to disclose sample size in exposure units, assumed observation process, prior information, parameter uncertainty, and sensitivity to distributional alternatives. A numerical estimate with six decimal places cannot substitute for a defensible evidence chain. When the approved business volume expands, posterior predictive uncertainty and correlated shocks must be reconsidered using a model appropriate to the enlarged exposure.
Validation, scoring, and performance feedback
For forecastable outcomes, validation must distinguish calibration, discrimination, stability, and decision usefulness. Gneiting and Raftery (2007) explain why proper scoring rules assess probabilistic forecasts without creating incentives to misreport beliefs under their framework. Such rules can be useful when comparing predictive models with observable outcomes. Their use requires attention to event definitions, a relevant evaluation sample, data leakage, time-dependent drift, and whether claims have matured.
A product with a sparse initial claims history can employ prospective backtesting as exposure accumulates, but early non-events should not be overinterpreted. Validation also requires independent legal and operational testing, including whether a simulated claim under the actual wording produces the expected payout. A technically accurate hazard probability can support a poorly drafted contract; conversely, clear contractual terms can be paired with unstable frequency estimates.
Data governance should specify lineage, lawful use, missingness, update frequency, revision responsibility, and the effect of third-party transformations. Independence of challenge concerns the ability to question inputs and decisions, not an absolute requirement that model validators have no knowledge of the business. The essential scientific test is whether an independent reviewer can reconstruct the calculation and identify the assumptions on which approval rests.
Nonstationarity, accumulation, and risk transfer
Innovations frequently encounter nonstationary hazards: exposure behavior changes with incentives, technology evolves, legal doctrine shifts, and claims reporting improves. Model fitting to a historical window alone can create a false impression of stability. For cyber products, a change in the prevalence of a dominant software supplier can alter dependence even if individual firms' estimated attack frequencies remain unchanged. For climate-linked policies, the physical event and the insured loss can diverge because of differences in location, vulnerability, or adaptation.
A reinsurance program can reduce retained exposure only within its coverage and credit assumptions. The product review must align insured event definitions, aggregation clauses, occurrence and claims-made provisions where relevant, territorial boundaries, attachment points, exclusions, and settlement timing. Residual basis risk between the direct policy and reinsurance should be explicitly documented. The IAIS supervisory framework and Solvency II's reinsurance risk scope make risk mitigation part of enterprise risk management, but neither source guarantees that any particular transfer is effective.
Uncertain information also changes the correct decision horizon. A product with claims settling over many years can require monitoring horizons longer than its initial commercial launch period. The insurer should therefore describe both when it expects to learn and whether that learning can arrive in time to prevent material loss. Governance that relies on future evidence without considering the timing of irreversible exposure has accepted an implicit financing and risk-bearing decision.
Legal and Technology Dependencies
Regulatory architecture and jurisdiction-specific consequences
A cross-border product can be governed by rules concerning insurance authorization, distribution, consumer information, pricing, data processing, technology outsourcing, solvency, and claims conduct. The operative legal standard depends on where risk is located, who manufactures or distributes the product, what legal entity carries the liability, and which customer and policy class are involved.
The EU product-oversight delegated regulation directly addresses manufacturers and distributors in its defined scope. The EU Solvency II regime addresses insurer governance and solvency. For relevant UK insurance products, the FCA PROD 4 handbook contains the applicable product-governance requirements, with additional provisions and effective dates that have evolved after EU withdrawal. A US rate and form filing moves through state systems such as SERFF, while the substantive filing and approval duties must be determined in each relevant state. The NAIC model AI bulletin offers state insurance departments a template; it is not automatically binding law in every state.
This comparison rejects the assumption that a single international new-product license or a universal insurance innovation gate exists. The substantive commonality is an analytical need to coordinate liability, evidence, and customer effects; the legal authority and required formal procedure differ. A global insurer should maintain a jurisdiction-by-jurisdiction compliance crosswalk instead of labeling every internal process 'required under international law.'
Ownership of risk across manufacturers, brokers, and platforms
A product may be conceived by a technology provider, underwritten by a licensed insurer, marketed by a broker, and serviced by a separate claims administrator. Governance is fragmented when each participant regards a major decision as someone else's responsibility. Who chooses the insured event, sets the price, designs the exclusion, controls the sales interface, and changes the model determines where operational influence lies.
The European rules on manufacturing responsibility require examination of actual decision rights when intermediaries design essential features. For embedded insurance, a checkout interface can produce inconsistent target-market outcomes even if policy wording is legally valid. Distribution incentives and commissions should therefore be understood within the product's total customer price and service value.
Third-party involvement creates distinct contractual and informational risks. A platform may know which customer rejected or accepted insurance, while the risk carrier sees only bound policies. Selection effects in that observed portfolio then undermine the carrier's pricing assumptions. Agreement over data access, audit rights, version control, and procedures for suspension becomes a condition of credible postlaunch monitoring. A product-governance signature without access to the underlying exposure and claims denominators cannot establish that ongoing review is effective.
AI-supported products and the limits of automation
Algorithmic underwriting, risk scores, adaptive distribution, fraud detection, and automated claims assessment can widen the number of decisions made without direct human intervention. Their governance problem is a combination of prediction quality, lawful data use, fairness, error correction, and institutional accountability. A model's output is an input into an insurer's contractual action and must be traceable to the applicable decision standard.
The 2025 EIOPA AI-governance opinion clarifies supervisory expectations under existing insurance-sector legislation, using a proportional and risk-based approach. EIOPA states that this opinion does not create new requirements, and its specific scope excludes AI systems categorized as high-risk or prohibited under the EU AI Act. That scope must be maintained when drawing conclusions about life and health insurance pricing. The 2023 NAIC model bulletin similarly describes governance, documentation, monitoring, and third-party AI systems across the insurance life cycle, as a model for state-level regulatory adoption.
The NIST AI Risk Management Framework, published in 2023 and under revision as of the research cutoff, is voluntary technical guidance. It offers useful language for mapping and measuring risks but cannot replace an insurer's applicable statutory obligations. The core operational conclusion is that responsibility for an adverse insurance decision persists when a system vendor provides a prediction. Launch approval must therefore define permissible automated actions, human review pathways, appeals, data revision controls, and rollback triggers.
ICT, outsourcing, and correlated service failure
A digital insurance product is partially implemented through its software and service suppliers. An apparently narrow coverage promise can become nonperforming if a cloud outage prevents claims notification, a security failure corrupts loss evidence, a trigger feed is unavailable, or an automated claims function cannot be reversed. These are insurance contract-performance risks as well as technology risks.
The EU Digital Operational Resilience Regulation, known as DORA, has applied since January 17, 2025 to financial entities within its scope. It addresses governance of ICT risk, dependencies, incident management, resilience testing, and third-party ICT risk. Its applicability and proportional treatment must be verified for the specific insurance undertaking, including statutory exclusions. The NIST Cybersecurity Framework 2.0 is voluntary and supplies a complementary governance taxonomy, rather than a substitute for applicable DORA obligations.
An insurer introducing an automated payout service should test the consequences of corrupted sensor data, failed authentication, supplier insolvency, a change in an application programming interface, or prolonged unavailability. These tests belong before launch because customers and intermediaries may rely on promised speed or automatic payment as a material product feature. A workable contingency must define who can determine the insured event during an outage, whether evidence can be restored, how policyholders are informed, and how the insurer reconciles delayed payments.
Innovation evidence, market conduct, and comparative supervision
The EIOPA digitalization study of 2024 describes opportunities and challenges in the deployment of digital services, including new forms of product design and distribution. Its survey-based observations concern participants and the period researched; they are not a causal assessment of individual product launches. EIOPA's 2023 product-governance peer review examined the maturity of national supervision, and the June 2026 follow-up reports progress alongside uneven supervisory capabilities across Member States. These documents substantiate the need to distinguish formally established supervisory processes from their practical intensity.
The UK adds unusually observable public outcome information. The FCA's 2025 value-measures release, published in 2026, provides aggregate and firm-specific indicators for defined general-insurance classes, subject to reporting thresholds and data-quality constraints. The September 2026 post-implementation review reports improved transparency from the reporting framework while identifying inconsistent data that limit cross-firm comparison. This simultaneous evidence of usefulness and measurement problems illustrates a central scientific point: governance requires scrutiny of the performance indicator itself.
Postlaunch Surveillance and Corrective Action
The product after launch remains a changing experiment in risk exposure
Launch is the beginning of realized experience, not the conclusion of risk review. Growth changes the distribution of policyholders; competitors and intermediaries change the pool of applicants; new litigation changes claims interpretation; technology changes the cost of service; and emerging hazards change loss correlation. Postlaunch monitoring must therefore test the product's actual behavior against the assumptions on which authorization rested.
The delegated EU monitoring requirements require regular product review, attention to material events and target-market consistency, and appropriate mitigation when product-related circumstances adversely affect customers. Article 7 connects monitoring to corrective action and communication with distributors and customers. This imposes a concrete interpretive limit on a 'set and forget' approach; documented formal approval without effective review fails to address a statutory stage of the product lifecycle.
For scientific analysis, the core monitoring question is counterfactual: would the product have been authorized at the same exposure scale if the observed information had been available at the original decision? This is an analytical comparison that can reveal stale assumptions even when the newest business results appear favorable.
Selecting meaningful indicators and denominators
A surveillance record should preserve exposure-years, sums insured, policy durations, premiums, claims reported and settled, ultimate loss estimates, claim rejection reasons, complaints, renewal behavior, customer population, acquisition costs, and distribution channels. For parametric products, it should additionally track trigger measurements, actual observable harm, missed payments following damaging events, and payments without material harm. For automated products, audit records should link model version to decision, appeals, error correction, and human override.
The FCA 2025 general-insurance measures report claims frequency, acceptance rates, average payouts, complaints, and claims cost as a proportion of premiums. The same official release cautions that product age, business mix, premium and claim timing, inflation, and inconsistent reporting complicate interpretation. It reports home-insurance acceptance rates of approximately 62–71% in the stated aggregation and higher ranges for travel and motor; these are descriptive observations from the regulator's reporting population, not product-level judgments on any individual insurer.
A low claims ratio can arise from effective prevention, low expected event frequency, exclusions that limit usable protection, immature claims, or high premiums. A high claims ratio can reflect valuable coverage, inadequate pricing, shock losses, or reserve development. Neither number alone establishes customer value or solvency. Proper surveillance therefore links the quantitative indicator to the product's promise and the actual claims pathway.
Review triggers, thresholds, and uncertainty
A trigger is a rule for returning a decision to authorized scrutiny. Examples include an unexpected concentration in a peril zone, materially unfavorable ultimate claims development, a policy-wording dispute replicated across customers, a supplier outage compromising service levels, a drift in underwriting data, or a disproportionate concentration of declined claims in a defined customer group. The number and magnitude of triggers should respond to product size, duration, and reversibility.
Triggers need statistical and operational interpretation. With sparse claims, a single large loss may be a possible event under the original model; under mass-market distribution, a small but systematic error rate can produce widespread customer harm. Review thresholds should therefore combine effect size, exposure count, data maturity, severity, confidence, and legal importance. A target-market integrity failure may require action even before statistical significance is established.
The FCA product-governance thematic review documents a supervisory concern about inadequate product-value evidence and inadequate corrective action. The practical lesson is that a control must specify what happens when a warning is observed. A metric without a named decision-maker and an authorized response is informational decoration.
Corrective action and the limits of withdrawal
Possible responses include clearer information, modification of eligibility, repricing subject to legal restrictions, alteration of cover for future contracts, adjusted distribution channels, vendor remediation, enhanced claims service, additional reinsurance, business-volume limits, suspension of new sales, and orderly discontinuation. The choice depends on existing contractual commitments, legal constraints, customer impact, reserves, and alternatives. Discontinuing new sales does not erase obligations under policies already written.
The product's corrective-action plan must distinguish new business, renewals, and existing insureds. In a long-tail product, claims may emerge after new issuance ends. The insurer must maintain administrative capacity, data access, reinsurance recoverability, and reserve assessment for the remaining book. A withdrawal decision may reduce future exposure while temporarily worsening per-policy servicing cost and liquidity. These effects must be reported as part of the exit decision.
The EU product-governance regulation expressly refers to mitigating customer detriment and informing affected parties when appropriate. The insurer's internal authority should consequently encompass customer remediation, not solely the protection of expected margin. The difference matters when a product passes a solvency test while systematically failing to pay in the circumstances most salient to customers.
Evidence of effectiveness and the researchable governance question
The most convincing evidence of effective product governance would connect a documented decision or changed control to an observable outcome under a credible identification design. A firm could compare product cohorts before and after a wording revision, examine a staggered rollout across channels, or use carefully matched cohorts to test whether claims disputes or errors changed. Such studies must adjust for changing exposure, customer selection, calendar effects, legal changes, and reporting practices.
The ERM literature demonstrates why simple before–after comparisons are insufficient. Hoyt and Liebenberg (2011) and McShane and colleagues (2011) obtain different findings about firm value from different risk-management measures. Neither substitutes for a well-identified product-gate evaluation. Likewise, FCA thematic supervision provides direct evidence of observed deficiencies but is not an intervention trial establishing the precise causal value of more committee meetings.
Research on innovation governance would benefit from linked insurer-level records covering proposals accepted and rejected, model uncertainty disclosed at decision time, conditions of approval, subsequent product changes, actual target-market outcomes, claims performance, and risk-adjusted growth. Absent such records, the conclusion that controls are necessary for disciplined decisions is institutionally and analytically supported; a precise estimate of their net economic return is beyond the evidence.
Comparative Synthesis and Research Conclusions
The international comparison of authority and evidence
The principal jurisdictions and standard-setting bodies illuminate different constraints. EU insurance distribution law specifies a product lifecycle with target-market and continuing monitoring duties. EU prudential law integrates new risks with enterprise risk and capital. UK product rules emphasize demonstrable value and substantive product governance, with public value-measures data and supervisory reviews testing practice. US supervision is distributed across state enactments and filing systems, with NAIC models and guidance providing coordination and reference. IAIS, OECD, ISO, and NIST instruments articulate international or cross-sector expectations and tools with varying degrees of normative authority.
| Framework | Main object | Evidence required by the analytical comparison | Normative status |
|---|---|---|---|
| EU IDD and Delegated Regulation 2017/2358 | Product design, target market, distribution, monitoring, remediation | Customer needs, product testing, distribution and corrective-action record | EU law within stated scope |
| EU Solvency II | Integrated insurer risk management and solvency | Exposure, interdependence, risk appetite, capital and ORSA analysis | EU prudential law within stated scope |
| UK FCA PROD 4 | Product governance and fair value | Price-quality reasoning, target-market fit, review evidence | UK regulatory rules for covered products |
| US state insurance regulation and NAIC materials | State-specific insurance authority, rates/forms, ERM and technology | Jurisdictional legal crosswalk, filed forms, state-applicable governance | State law plus nonbinding NAIC models/guidance unless adopted |
| IAIS ICPs and OECD governance guidance | International supervisory and institutional governance | Roles, oversight, integrated risk control and policyholder protection | Supervisory standards/guidelines; implementation varies |
| ISO 31000 and NIST frameworks | General risk and technical governance methods | Documented risks, assumptions, monitoring and controlled change | Voluntary guidance unless separately incorporated |
The table is a comparative analytic synthesis, not a statement that these instruments have interchangeable legal effect. Its sources are the EU delegated POG rules, FCA PROD 4, NAIC ORSA guidance overview, IAIS ICP framework, and ISO 31000:2018.
This comparison supports a general proposition: the relevant control is the authority to decide over the combined exposure and performance of the product, exercised with evidence appropriate to its novelty and consequence. Specific committee names, annual schedules, or quantitative launch cutoffs cannot be deduced as universal obligations from these diverse instruments.
A comparative reading of product examples
Consider three purely hypothetical and intentionally stylized designs. A traditional household endorsement adds a small, legally familiar peril to an established customer population. A cyber offering covers a rapidly evolving software supply-chain interruption shared across many policyholders. A parametric weather policy promises fast cash following a gauge-based trigger but may leave losses unpaid when the gauge and insured location diverge.
The household endorsement may derive relevant frequency and severity information from existing claims, though wording and geographic aggregation still require review. The cyber product faces greater uncertainty about common failure, reporting, and changed attack behavior; the Biener–Eling–Wirfs empirical study gives historical evidence for these limitations. The parametric design can offer rapid, objective settlement if the trigger is independently reliable, but it may fail its protective purpose through basis risk. In all three, the control effort should depend on the severity and reversibility of possible error rather than the novelty of the product's marketing.
The comparison reveals two separate grounds for rejection. The first is epistemic: the insurer cannot defend the assumed distribution of losses or its capacity to pay under material alternative scenarios. The second is contractual or conduct-related: the product is likely to disappoint the identified target market despite technically correct operation. A third case concerns execution: the promises are coherent and theoretically priced, but necessary systems or partners cannot reliably deliver them. These are analytical categories useful for reading evidence; they are not a newly instituted theory of insurance.
Decision quality, speed, and innovation incentives
Risk governance can delay launch, impose costs, or constrain commercial experimentation. These effects are real and should be evaluated against avoided losses, improved claims performance, and the information gained. The correct comparison is not 'control versus innovation' in the abstract; it is the expected performance of alternative decision arrangements under uncertainty. Rapid launch can be justified for a small, reversible exposure with reliable monitoring, while a slow formal procedure can still be negligent if it suppresses dissent or overlooks correlated liabilities.
A disciplined organization allocates more evidence and independent challenge to risks with high severity, uncertain distribution, weak reversibility, significant customer reliance, and possible systemic accumulation. This allocation is consistent with the proportionality embedded in EU product approval requirements, the OECD insurer-governance guidance, and the general risk principles of ISO 31000. The exact operational arrangement must remain demonstrably adequate to the insurer and product.
Information quality is therefore a scarce resource in the launch decision. An additional committee that reviews unchanged documents adds little knowledge. A documented challenge that discovers an unrecognized claims exclusion, an unhedged cloud concentration, or a broken payment contingency can change the choice substantively. Measuring governance by the number of forms completed would miss its economic and protective function.
Institutional observations and the limits of causal inference
The supervisory record provides a useful test of the gap between written arrangements and operational execution. The FCA's TR24/2 review reported weaknesses in product governance and value evidence among sampled firms. EIOPA's 2026 POG follow-up report described enhanced supervision alongside cross-jurisdiction differences in maturity. The FCA post-implementation review in 2026 found that value-measures reporting improved transparency but also revealed inconsistent measurements.
These observations support a common interpretation: a product-control regime becomes more effective when information, authority, and remediation are operationally connected. Yet these institutional sources do not estimate a universal percentage reduction in losses or consumer harm from any specified control. Cross-country comparison is further limited by differences in product mix, reporting, legal scope, and supervision. Claims about specific causal treatment effects require better design and access to records than this documentary research can provide.
Research agenda and methodological implications
Empirical work should preserve each product's full decision history, including rejected proposals and conditions attached to approvals; otherwise selection into the observed launched-product sample biases conclusions. It should track model inputs at launch, subsequent revisions, and contemporaneous business context, with legal changes and catastrophe years independently recorded. Outcome measures should include claims adequacy, customer harm, unexpected accumulation, expenses, capital consumption, distribution integrity, and continuity of service.
A promising research design would examine a documented change in product committee authority introduced at different times across comparable portfolios, test parallel pretrends, and distinguish changes in product mix from improvements in outcomes for similar risks. Where such designs are infeasible, transparent event studies, structured qualitative case comparisons, and scenario-based audits are still informative within their stated limits. Proper probabilistic validation, in the sense discussed by Gneiting and Raftery (2007), would help evaluate the prediction component, while legal and operational tests assess performance outside the model's stochastic domain.
The substantive research conclusion is that governance quality is revealed by the traceability of consequential decisions: whether the institution can say what it believed, why it accepted the product, how it limited exposure, what it observed afterward, and how it changed course. This conclusion is grounded in documentary comparison, a transparent set of elementary actuarial calculations, and explicit limits of the available empirical evidence.
Conclusions
Risk governance of new insurance products is the continuing enterprise responsibility for accepting, delivering, monitoring, and, where needed, correcting a new contractual liability. Its object includes the risk carrier's capital and operational capacity together with the customer population, contract language, distribution behavior, and technologies on which performance depends. A satisfactory decision requires evidence about each of these dimensions and an accountable authority empowered to change the proposed launch.
The comparative legal analysis establishes the separate functions of EU product oversight and prudential supervision, UK product-value requirements, US state-based insurance authority, and international or voluntary governance guidance. Their substantive overlap is useful for comparative learning, while their legal effects remain jurisdiction-specific. Product approval must therefore be documented against the actually operative rules for the relevant insurer, customer, and distribution pathway.
The quantitative analysis establishes how parameter uncertainty and common-shock dependence can alter an apparently positive expected financial contribution. Its calculations are original hypothetical illustrations, with stated assumptions and replicable arithmetic; no causal or empirical estimate is attributed to them. Studies of ERM and firm value exhibit different associations across research designs and do not prove the value of a specific launch gate. Cyber-risk research and supervisory product reviews substantiate limitations of data, accumulation estimation, formal-control quality, and postlaunch evidence.
The resulting original analytical synthesis places decisive weight on source-traceable approvals, proportional independent challenge, explicit uncertainty, customer-purpose testing, technology resilience, and enforceable correction after launch. This is a conclusion about how existing obligations and evidence meet in a specific insurance decision, rather than a new named theoretical system. Future empirical work can assess its effectiveness by connecting archived launch decisions to mature policyholder and balance-sheet outcomes, while controlling for the selection and measurement problems identified here.
References
Biener, Christian, Martin Eling, and Jan Hendrik Wirfs. 2015. “Insurability of Cyber Risk: An Empirical Analysis.” The Geneva Papers on Risk and Insurance—Issues and Practice 40 (1): 131–158. https://alexandria.unisg.ch/entities/publication/9054bc0d-f4a7-4f46-a961-b804eef06f4d
Eling, Martin, and Werner Schnell. 2016. “What Do We Know About Cyber Risk and Cyber Risk Insurance?” Journal of Risk Finance 17 (5): 474–491. https://alexandria.unisg.ch/entities/publication/17442364-7c66-49c2-bce1-c95292b5305f
European Insurance and Occupational Pensions Authority (EIOPA). 2023. “Peer Review on Product Oversight and Governance (POG).” July 20. https://www.eiopa.europa.eu/publications/peer-review-product-oversight-and-governance-pog_en
European Insurance and Occupational Pensions Authority (EIOPA). 2024. “Report on the Digitalisation of the European Insurance Sector.” April 30. https://www.eiopa.europa.eu/publications/eiopas-report-digitalisation-european-insurance-sector_en
European Insurance and Occupational Pensions Authority (EIOPA). 2025. “Opinion on Artificial Intelligence Governance and Risk Management.” August 6. https://www.eiopa.europa.eu/publications/opinion-artificial-intelligence-governance-and-risk-management_en
European Insurance and Occupational Pensions Authority (EIOPA). 2026. “Follow-up Report to EIOPA’s Peer Review on Product Oversight and Governance (POG).” June 30. https://www.eiopa.europa.eu/publications/follow-report-eiopas-peer-review-product-oversight-and-governance-pog_en
European Parliament and Council. 2009, consolidated January 17, 2025. “Directive 2009/138/EC (Solvency II), Articles 41–48.” EUR-Lex. https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A02009L0138-20250117
European Parliament and Council. 2016, consolidated January 9, 2024. “Directive (EU) 2016/97 on Insurance Distribution, Article 25.” EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02016L0097-20240109
European Parliament and Council. 2022. “Regulation (EU) 2022/2554 on Digital Operational Resilience for the Financial Sector.” Official Journal of the European Union, December 27. https://eur-lex.europa.eu/eli/reg/2022/2554/oj?uri=CELEX%3A32022R2554
European Commission. 2017. “Commission Delegated Regulation (EU) 2017/2358 on Product Oversight and Governance Requirements for Insurance Undertakings and Insurance Distributors.” Official Journal of the European Union, December 20. https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX%3A32017R2358
Financial Conduct Authority (FCA). 2024, updated December 2025. “TR24/2: General Insurance and Pure Protection Product Governance Thematic Review.” August 21. https://www.fca.org.uk/publications/thematic-reviews/tr24-2-general-insurance-pure-protection-product-governance
Financial Conduct Authority (FCA). 2026a. “FCA Handbook: PROD 4—Product Governance: IDD and Pathway Investments.” Current handbook text as of research cutoff. https://handbook.fca.org.uk/handbook/prod4
Financial Conduct Authority (FCA). 2026b. “General Insurance Value Measures Data 2025.” July 21; updated September 11. https://www.fca.org.uk/data/general-insurance-value-measures-data-2025
Financial Conduct Authority (FCA). 2026c. “CP26/33: Consultation on Minor General Insurance Value Measures Changes and Post-Implementation Review of the Value Measures Rules.” September 11; updated October 19. https://www.fca.org.uk/consultation-papers/cp26-33-minor-general-insurance-value-measures-changes-post-implementation-review-value-measures-rules
Gneiting, Tilmann, and Adrian E. Raftery. 2007. “Strictly Proper Scoring Rules, Prediction, and Estimation.” Journal of the American Statistical Association 102 (477): 359–378. https://doi.org/10.1198/016214506000001437
Hoyt, Robert E., and Andre P. Liebenberg. 2011. “The Value of Enterprise Risk Management.” Journal of Risk and Insurance 78 (4): 795–822. https://doi.org/10.1111/j.1539-6975.2011.01413.x
International Association of Insurance Supervisors (IAIS). 2024. “Insurance Core Principles and ComFrame: December 2024 Update.” Overview and adopted framework. https://www.iais.org/activities-topics/standard-setting/icps-and-comframe/
International Organization for Standardization (ISO). 2018. “ISO 31000:2018 Risk Management—Guidelines.” Second edition. https://www.iso.org/standard/31000
McShane, Michael K., Anil Nair, and Elzotbek Rustambekov. 2011. “Does Enterprise Risk Management Increase Firm Value?” Journal of Accounting, Auditing & Finance 26 (4): 641–658. https://doi.org/10.1177/0148558X11409160
National Association of Insurance Commissioners (NAIC). 2023. “Model Bulletin: Use of Artificial Intelligence Systems by Insurers.” Adopted December 4. https://content.naic.org/sites/default/files/inline-files/2023-12-4%20Model%20Bulletin_Adopted_0.pdf
National Association of Insurance Commissioners (NAIC). 2026a. “Own Risk and Solvency Assessment.” Insurance Topics; overview of Model Act #505 and ORSA guidance. https://content.naic.org/insurance-topics/own-risk-and-solvency-assessment
National Association of Insurance Commissioners (NAIC). 2026b. “System for Electronic Rates and Forms Filing (SERFF).” Industry program overview. https://content.naic.org/industry/serff
National Institute of Standards and Technology (NIST). 2023. “Artificial Intelligence Risk Management Framework (AI RMF 1.0).” January 26. https://www.nist.gov/itl/ai-risk-management-framework
National Institute of Standards and Technology (NIST). 2024. “The NIST Cybersecurity Framework (CSF) 2.0.” NIST CSWP 29, February 26. https://www.nist.gov/publications/nist-cybersecurity-framework-csf-20
Organisation for Economic Co-operation and Development (OECD). 2017. “OECD Guidelines on Insurer Governance, 2017 Edition.” OECD Publishing, Paris. https://www.oecd.org/en/publications/2017/12/oecd-guidelines-on-insurer-governance-2017-edition_g1g879ca.html